Compare Main Street Capital Corporation (MAIN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Sanofi SA — how do they compare? Main Street Capital Corporation trades at $54.6 (market cap $5.08B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 20.6× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (8.02%). Which is the better fit depends on your goals.
| MAIN | SNY | |
|---|---|---|
Market Cap | $5.08B | $104.83B |
Sector | Financials | Health |
52-Week High | $67.54 | $52.34 |
52-Week Low | $49.63 | $41.33 |
Dividend Yield | 8.02% | 5.5% |
Enterprise Value | — | $121.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.19, down 2.13% today, with a bullish technical signal from moving averages. The stock shows strong profitability with an 81.08% net income margin and a P/E of 11.49, below industry averages. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains a consistent dividend history, with recent payouts of $0.27-$0.30 per share, supporting income-focused investors.
Outlook remains cautious with 78.57% of analysts rating Hold, citing potential earnings softness. The consensus price target is $57.75, offering modest upside. Key risks include declining revenue projections for 2026 and negative operating cash flow. MAIN's premium valuation relative to book value is justified by cost advantages, but investors should monitor earnings sustainability amid economic headwinds.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
